PD-1 Blockade in Early-Stage Lung Cancer.
Annu Rev Med
; 70: 425-435, 2019 01 27.
Article
em En
| MEDLINE
| ID: mdl-30355264
ABSTRACT
Early-stage non-small cell lung cancer is a potentially curable disease, but with relapse rates exceeding 50% with standard treatments, this is a patient population in critical need of therapy innovation. Immunotherapy with immune checkpoint blockade has revolutionized the treatment strategy for advanced lung cancer. However, the role of this therapy in earlier-stage disease is largely unknown. The study of immunotherapy in earlier-stage disease has many advantages, including assessment of pathologic response and incorporation of translational scientific analyses to evaluate antitumor immune responses. Multiple clinical trials are currently under way, with promising early results.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Receptor de Morte Celular Programada 1
/
Antineoplásicos Imunológicos
/
Nivolumabe
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article